Gilead's Twice-Yearly Lenacapavir Reduces HIV Infection Risk
According to a study published in the New England Journal of Medicine, twice-yearly injection of Lenacapavir offers a 96 percent ...
Gilead Stock Surges 44.2% in 6 Months: Time to Buy or Sell?
GILD has put up a solid performance in the past six months on positive data readouts and strong quarterly results. We believe ...
bovnews21h
What Factors Have Led to Gilead Sciences, Inc. (GILD) Stock Trading -6.56% Below Its 52-Week High?
On Wednesday, Gilead Sciences, Inc. (GILD) stock saw a modest uptick, ending the day at $92.41 which represents a slight increase of $1.06 or 1.16% from the prior close of $91.35. The stock opened at ...
GILD vs. VRTX: Which Stock Should Value Investors Buy Now?
Right now, Gilead Sciences is sporting a Zacks Rank of #2 (Buy), while Vertex Pharmaceuticals has a Zacks Rank of #3 (Hold). Investors should feel comfortable knowing that GILD likely has seen a ...